Parkinson's Disease Stem Cell Therapy by R3 International | Dr. David Greene

A renowned regenerative medicine company R3 Stem Cell, founded by Dr. David Greene Arizona in 2013, offers treatment for ailments including arthritis, diabetes, Stroke, Knee pain, Multiple Sclerosis, ALS, and many other diseases including Parkinson's Disease. R3 Internation offers treatment for Parkinson's disease with stem cells and exosomes at numerous locations in Mexico, Pakistan and others.

 Parkinson's disease (PD) is the second most prevalent progressive neurodegenerative disorder that is characterized by relatively focal degeneration of midbrain dopamine (mesDA) neurons. This issue occurs in ONE area of the midbrain called the substantia nigra pars compacta. The loss of dopamine-producing neurons results in a subsequent deficit in dopamine.    

The prevalence of PD in those over 65 years old is 2% with men being affected 50% more than women. It is a movement disorder that causes varying symptoms such as bradykinesia, resting tremor, and muscle rigidity, added Dr. David Greene R3 Stem Cell CEO. Impaired balance and coordination occur, sometimes leading to falls. Difficulty walking and talking may ensue as well. 

The gold standard treatment for PD is levodopa, which is combined with carbidopa to prevent nausea and vomiting. Complications include end-of-dose wearing off and levodopa-induced dyskinesia. Other common adverse effects include hallucinations, impulse control disorders, and other psychiatric problems.

Deep brain stimulation (DBS) is commonly used when medical therapy is exhausted in an attempt to normalize motor function.

The optimal treatment is one that would enter the brain and actually be neuroprotective and neuroregenerative. Initial research into the effects of stem cells on the brain show excellent effects for: 

 

• Neurogenesis 
• Revascularization 
• Anti-apoptosis 
• Immunomodulatory 
• Anti-inflammatory

 

Given the ability to migrate and engraft at sites of inflammation and injury, most of the effects are exerted by their cell-to-cell communication along with neurotrophic factors and cytokines.

A 2017 study in Neural Regeneration Research showed that the umbilical cord maintains an unlimited source of cells differentiable towards dopaminergic neurons. A study the following year in the Journal of Chemical Neuroanatomy showed that Wharton’s Jelly derived mesenchymal stem cells may be a great source for the production of dopamine-producing neurons.

A 2010 study out of Translational Research included seven PD patients receiving bone marrow derived stem cells directly into the brain. Three out of the seven showed dramatic improvements, and no adverse events were seen.

R3 Stem Cell International has treated over 50 patients with PD to date, using intrathecal umbilical cord stem cells numbering between 50 million up to a billion cells. Patients have seen substantial improvements, with no significant adverse events to date.